Ab­b­Vie's Phar­ma­cyclics files patent suit against BeiGene over BTK ri­val Brukin­sa

Phar­ma­cyclics is bring­ing its BTK bat­tle to court.

The Ab­b­Vie unit filed suit against BeiGene on Tues­day, al­leg­ing the com­pa­ny’s com­pet­ing blood can­cer drug Brukin­sa in­fringes on a new patent around Im­bru­vi­ca.

The patent in ques­tion, dubbed ‘803, was is­sued on Tues­day, the same day Phar­ma­cyclics filed its com­plaint in Delaware fed­er­al court. It cov­ers meth­ods for us­ing a BTK in­hibitor of cer­tain chem­i­cal struc­ture for chron­ic lym­pho­cyt­ic leukemia and small lym­pho­cyt­ic lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER